SLDB

Solid Biosciences Inc.

NasdaqGSUSDEQUITY DELAYED

9.30

▲ 0.20 (2.20%)

MARKET · —

Price

Open

8.86

Prev close

9.10

Day high

9.67

Day low

9.23

Volume

781.17K

Market cap

—

P/E (TTM)

—

52W range

3.79 – 11.45

Trailing performance

Price return · vs SPY

Returnvs SPY

+1.09% +2.5%

+16.54% +12.8%

+43.08% +40.0%

+62.87% +51.8%

YTD

+64.89% +52.6%

+64.31% +44.3%

+147.34% +73.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

9.11

+2.11% from price

SMA 20

8.70

+6.90% from price

SMA 50

8.92

+4.32% from price

SMA 100

8.15

+14.16% from price

SMA 200

7.03

+32.26% from price

EMA 12

9.06

+2.70% from price

EMA 26

8.89

+4.61% from price

EMA 50

8.67

+7.28% from price

RSI (14)

56.2

Neutral

MACD (12,26,9)

0.17

Hist 0.09

ATR (14)

0.50

5.38% of price

Realised vol 30D

56.6%

Annualised

Bollinger upper

9.71

20, 2σ

Bollinger lower

7.69

20, 2σ

50 / 200 cross

Golden

8.92 vs 7.03

Trend bias

Above 200

+32.26%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.06

More volatile than market

Correlation to SPY

0.33

Loosely linked

Realised vol 30D

56.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-38.6%

Peak to trough

Max drawdown 5Y

-96.1%

Peak to trough

ATR 14

0.50

5.38% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 9.30

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

SLDB · links out to the publisher

Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating MT Newswires · 15d ago Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 16d ago Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base? Simply Wall St. · 52d ago Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says MT Newswires · 65d ago BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors TMX Newsfile · 76d ago Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics PR Newswire · 81d ago Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 82d ago Solid Biosciences to Participate at Upcoming Investor Conferences GlobeNewswire · 82d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.